Compound 8c

The designation **Compound 8c** is a non-specific label frequently used in medicinal chemistry literature to identify a lead molecule within a specific research series. In the biotechnology sector, this name most prominently refers to two distinct, high-impact research compounds. The first is a potent, selective, and orally bioavailable **BACE1 (beta-secretase 1) inhibitor** developed by **Merck & Co.**, which served as a critical structural lead in the discovery of the clinical candidate **verubecestat** (MK-8931) for Alzheimer's disease. The second is a systemic **STING (Stimulator of Interferon Genes) agonist** developed by **Bristol Myers Squibb**, which represented a breakthrough in identifying non-nucleotide, small-molecule STING activators suitable for systemic administration in oncology. Additionally, the label has been applied to potent inhibitors of the **NLRP3 inflammasome** and the **SARS-CoV-2 main protease (Mpro)** in various academic studies.